TITLE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

AUTHOR(S)
Riddle, Matthew C.; Bolli, Geremia B.; Ziemen, Monika; Muehlen-Bartmer, Isabel; Bizet, Florence; Home, Philip D.
PUB. DATE
October 2014
SOURCE
Diabetes Care;Oct2014, Vol. 37 Issue 10, p2755
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin. RESEARCH DESIGN AND METHODS EDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallel-group study. Adults with glycated hemoglobin A1c (HbA1c) 7.0-10.0% (53-86 mmol/mol) were randomized to Gla-300 or Gla-100 once daily with dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L. Primary end point was HbA1c change from baseline; main secondary end point was percentage of participants with one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemia from week 9 to month 6. RESULTS Participants (n = 807) had mean age 60 years, diabetes duration 16 years, BMI 36.6 kg/m², and HbA1c 8.15% (65.6 mmol/mol). HbA1c reduction was equivalent between regimens; least squares mean difference -0.00% (95% CI -0.11 to 0.11) (-0.00 mmol/mol [-1.2 to 1.2]). Fewer participants reported one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemic events between week 9 and month 6 with Gla-300 (36 vs. 46%with Gla-100; relative risk 0.79 [95% CI 0.67-0.93]; P < 0.005); nocturnal hypoglycemia incidence and event rates were also lower with Gla-300 in the first 8 weeks of treatment. No between-treatment differences in tolerability or safety were identified. CONCLUSIONS Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.
ACCESSION #
98499816

 

Related Articles

  • Interpreting hemoglobin A1c in diabetics. R.M.D. // Cortlandt Forum;6/25/96, Vol. 9 Issue 6, p74 

    Presents answers to the queries regarding the usefulness of monitoring glycosylated hemoglobin (HbA1c) levels in the management of diabetes. Information provided by measurements of HbA1c; Proportion of Hb1Ac to blood sugar levels; Factors affecting the levels; Book on the topic.

  • Antidiabetic, hypolipidemic and antioxidant properties of Asystasia gangetica in streptozotocin-nicotinamide-induced type 2 diabetes mellitus (NIDDM) in rats. Kuppusamy, Asok Kumar; Muthusamy, Umamaheswari; Shanmugam, Somanathan Sathravada; Thirumalaisamy, Sivashanmugam Andichetiar; Varadharajan, Subhdradevi; Ramanathan, Sambathkumar // Journal of Pharmacy Research;Oct2010, Vol. 3 Issue 10, p2516 

    Asystasia gangetica L. (Acanthaceae) is used in treatment of asthma, worm infestation and diabetes and was evaluated using streptozotocin-nicotinamide-induced type 2 diabetes mellitus in rats. Oral administration of A. gangetica leaf extract (AGLE) at doses of 100 and 200 mg/kg b. w. for 28 days...

  • Multivariate analysis of glycosylated haemoglobin in insulin-treated diabetics. Child, D. F.; Wood, Jane; Hudson, P. R.; Williams, C. P.; Roberts, D. R.; Smith, C. // Journal of the Royal Society of Medicine;Jul1985, Vol. 78 Issue 7, p549 

    Glycosylated haemoglobin (HbA1), as an assessment of overall control, was estimated in 858 insulin-treated diabetics attending for changeover to U100 insulin in North East Wales. Details of age, sex, duration of diabetes, insulin regimen and monitoring method were recorded. Multivariate analysis...

  • Insulin Edema in a Patient With Cystic Fibrosis--Related Diabetes. O'Neal, Katherine S.; Francis, Bethany A.; Condren, Michelle E.; Chalmers, Laura J. // Diabetes Care;Feb2012, Vol. 35 Issue 2, pe6 

    The article describes the case of a 23-year-old woman with cystic fibrosis-related diabetes (CFRD) who developed insulin edema. Among the factors that increase the risk of insulin edema are newly started insulin treatment and underweight. The patient received insulin pump at the age of 16 before...

  • Inhaled Insulin matches standard insulin in efficacy while offering easier use.  // Formulary;Aug2001, Vol. 36 Issue 8, p568 

    Reveals that inhaled insulin matches standard insulin in efficacy in glycemic control. Achievement of target hemoglobin A[sub lc] levels in a greater share of patients with type 2 diabetes; Potential of inhaled insulin for replacing injected insulin; Overcoming of patients' reluctance for...

  • Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy (CIT) and a 13-Point Method Designed to Enhance Compliance. Guevara-Aguirre, Jaime; Guevara-Aguirre, Marco; Saavedra, Jeannette; Bernstein, Gerald // Diabetes;Jun2007 Supplement 1, Vol. 56, pA615 

    The article discusses a study on the normalization of metabolic control on type-1 DM using conventional insulin therapy (CIT) and a 13-point method that are designed to enhance compliance. The study measured the fructosamine and glycated hemoglobin in diabetic subjects every two weeks. The...

  • Metabolic Improvement and Reducation of Severe Hypoglycemia After an Outpatient Education for Functional Insulin Therapy in Adult Type 1 Diabetic Patients. Janez, Andrej; Bizjak, Neli; Prezelj, Janez // Diabetes;Jun2007 Supplement 1, Vol. 56, pA616 

    Introduction: Functional insulin therapy (FIT) is a teaching approach of intensified insulin therapy. Its aim is to educate the patient about the management of its insulin treatment, according to the various acts of everyday life, and particulary meals. The aim of the study was to assess the...

  • Real Life Data on the Switch from Nph to Glargine in Type 1 Diabetics. McEwan, Phil; Sharplin, Peter; Mehin, Nazanin; Tetlow, Tony // Diabetes;Jun2007 Supplement 1, Vol. 56, pA658 

    This study is a real life evaluation of glycemic control in Type 1 diabetes' patients who are introduced to insulin glargine therapy after switching from NPH therapy. Based on data from the THIN database (The Health Improvement Network), a UK GP database including 2,335,667 patients followed...

  • Is Australia ready to use glycated haemoglobin for the diagnosis of diabetes? Shaw, Jonathan E.; d'Emden, Michael C.; Goodall, Ian // Medical Journal of Australia;7/4/2011, Vol. 195 Issue 1, p7 

    The article examines whether glycated haemoglobin could be used as a practical alternative to blood glucose for the diagnosis of diabetes in Australia. According to the author, since 1996, glycated haemoglobin has been recommended as the primary tool for assessing glycaemic control in people...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics